Selective Induction of Host Genes by MVA-B, a Candidate Vaccine against HIV/AIDS
暂无分享,去创建一个
Felipe García | T. Gallart | J. Gatell | H. Reyburn | Susana Guerra | M. Esteban | L. López-Fernández | C. E. Gómez | N. Climent | José M González | J. L. Nájera
[1] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[2] P. Earl,et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. , 2009, Vaccine.
[3] S. Akira,et al. Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome , 2009, PLoS pathogens.
[4] W. Cruikshank,et al. Human Immunodeficiency Virus Type 1 gp120 Reprogramming of CD4+ T-Cell Migration Provides a Mechanism for Lymphadenopathy , 2009, Journal of Virology.
[5] W. Kastenmuller,et al. Modified Vaccinia Virus Ankara Triggers Chemotaxis of Monocytes and Early Respiratory Immigration of Leukocytes by Induction of CCL2 Expression , 2009, Journal of Virology.
[6] P. Earl,et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. , 2008, The Journal of infectious diseases.
[7] H. Rammensee,et al. Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA1 , 2008, The Journal of Immunology.
[8] M. Feinberg,et al. Dendritic Cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo , 2008, BMC Immunology.
[9] M. Krupa,et al. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. , 2008, Current gene therapy.
[10] B. León,et al. Monocyte migration to inflamed skin and lymph nodes is differentially controlled by L-selectin and PSGL-1. , 2008, Blood.
[11] S. H. van der Burg,et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic , 2008, Proceedings of the National Academy of Sciences.
[12] J. Heeney,et al. Differential CD4 (cid:1) versus CD8 (cid:1) T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates (cid:1) † , 2022 .
[13] S. Akira,et al. Modified Vaccinia Virus Ankara Induces Toll-Like Receptor-Independent Type I Interferon Responses , 2007, Journal of Virology.
[14] G. González-Aseguinolaza,et al. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. , 2007, The Journal of general virology.
[15] T. Gallart,et al. Distinct Gene Expression Profiling after Infection of Immature Human Monocyte-Derived Dendritic Cells by the Attenuated Poxvirus Vectors MVA and NYVAC , 2007, Journal of Virology.
[16] G. Pantaleo,et al. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. , 2007, Vaccine.
[17] G. Pantaleo,et al. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. , 2007, Vaccine.
[18] Á. Zaballos,et al. Human Gene Profiling in Response to the Active Protein Kinase, Interferon-induced Serine/threonine Protein Kinase (PKR), in Infected Cells , 2006, Journal of Biological Chemistry.
[19] M. Carroll,et al. Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial , 2006, Clinical Cancer Research.
[20] S. Chisholm,et al. Recognition of Vaccinia Virus-Infected Cells by Human Natural Killer Cells Depends on Natural Cytotoxicity Receptors , 2006, Journal of Virology.
[21] M. Esteban,et al. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. , 2006, Microbes and infection.
[22] A. Pascual-Montano,et al. Host Response to the Attenuated Poxvirus Vector NYVAC: Upregulation of Apoptotic Genes and NF-κB-Responsive Genes in Infected HeLa Cells , 2006, Journal of Virology.
[23] T. Gallart,et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Coligan,et al. Cutting Edge: NKG2D Is a Costimulatory Receptor for Human Naive CD8+ T Cells , 2005, The Journal of Immunology.
[25] J. Sirard,et al. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. , 2004, Vaccine.
[26] K. Harshman,et al. Microarray Analysis Reveals Characteristic Changes of Host Cell Gene Expression in Response to Attenuated Modified Vaccinia Virus Ankara Infection of Human HeLa Cells , 2004, Journal of Virology.
[27] Robert S Negrin,et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. , 2004, Blood.
[28] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[29] G. McFadden,et al. Poxviruses and immune evasion. , 2003, Annual review of immunology.
[30] Mario Roederer,et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells , 2003, Nature Medicine.
[31] J. Carrascosa,et al. Differences in Virus-Induced Cell Morphology and in Virus Maturation between MVA and Other Strains (WR, Ankara, and NYCBH) of Vaccinia Virus in Infected Human Cells , 2003, Journal of Virology.
[32] C. Staib,et al. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. , 2003, Current drug targets. Infectious disorders.
[33] A. García-Sastre,et al. Prime-Boost Immunization Schedules Based on Influenza Virus and Vaccinia Virus Vectors Potentiate Cellular Immune Responses against Human Immunodeficiency Virus Env Protein Systemically and in the Genitorectal Draining Lymph Nodes , 2003, Journal of Virology.
[34] K. Harshman,et al. Cellular Gene Expression Survey of Vaccinia Virus Infection of Human HeLa Cells , 2003, Journal of Virology.
[35] T. Reinhart,et al. Simian immunodeficiency virus dramatically alters expression of homeostatic chemokines and dendritic cell markers during infection in vivo. , 2003, Blood.
[36] A. Moretta. Natural killer cells and dendritic cells: rendezvous in abused tissues , 2002, Nature Reviews Immunology.
[37] C. Yee,et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.
[38] G. McFadden,et al. Viral chemokine‐binding proteins , 2002, Journal of leukocyte biology.
[39] Richard A Lempicki,et al. HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[40] R. Biassoni,et al. Natural Killer Cells: A Mystery No More , 2002, Scandinavian journal of immunology.
[41] R. Darnell,et al. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells , 2001, Nature Immunology.
[42] Ira Mellman,et al. Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.
[43] D. Spehner,et al. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. , 2000, Virology.
[44] J. Carrascosa,et al. The vaccinia virus 39-kDa protein forms a stable complex with the p4a/4a major core protein early in morphogenesis. , 1999, Virology.
[45] M. Plana,et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. , 1999, AIDS.
[46] A Steinle,et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.
[47] J. Ramírez,et al. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. , 1999, Journal of immunology.
[48] Polly Matzinger,et al. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.
[49] P. Benias,et al. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. , 1998, Journal of immunological methods.
[50] F. Falkner,et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.
[51] A. Alcamí,et al. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. , 1998, The Journal of general virology.
[52] Marion Becker,et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.
[53] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[54] A. Alcamí,et al. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. , 1998, Journal of immunology.
[55] B. Moss. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[56] M. Esteban,et al. Vaccinia virus A17L gene product is essential for an early step in virion morphogenesis , 1995, Journal of virology.
[57] D. Goeddel,et al. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.
[58] J. F. Rodríguez,et al. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[59] H. Stickl,et al. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. , 1978, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, Betriebshygiene, praventive Medizin.
[60] V. Hochstein-Mintzel,et al. [Oral and nasal immunization with poxvirus vacciniae. IV. Studies of oral immunization in monkeys]. , 1973, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, praventive Medizin.
[61] V. Hochstein-Mintzel,et al. [Oral and nasal immunization with Poxvirus vacciniae. 3. Animal experiments]. , 1972, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, praventive Medizin.
[62] V. Groh,et al. Immunobiology of human NKG2D and its ligands. , 2006, Current topics in microbiology and immunology.
[63] J. Coligan,et al. NKG2D is a costimulatory receptor for human naive CD8+ T cells. , 2005, Journal of immunology.
[64] Z. Rosenberg,et al. Microbicides urgently needed: statement by IPM CEO, Zeda Rosenberg, on new AIDS statistics. Joint United Nations Programme on HIV/AIDS (UNAIDS) releases the 2004 AIDS epidemic update. , 2004 .
[65] S. Riddell,et al. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. , 2001, Nature immunology.
[66] S. Kunkel,et al. Chemokines and innate immunity. , 2000, Reviews in immunogenetics.
[67] B. Moss,et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. , 1996, Advances in experimental medicine and biology.
[68] D. Goeddel,et al. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. , 1995, Cell.
[69] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[70] H. Stickl,et al. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. , 1978 .